Pages that link to "Q34091087"
Jump to navigation
Jump to search
The following pages link to Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis (Q34091087):
Displaying 50 items.
- Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs (Q21089606) (← links)
- New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast (Q22305855) (← links)
- Promising new treatments for psoriasis (Q24598008) (← links)
- Recent advances in understanding psoriasis (Q26751223) (← links)
- Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast (Q26781755) (← links)
- Putting together the psoriasis puzzle: an update on developing targeted therapies (Q27026785) (← links)
- Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis (Q27693878) (← links)
- New Oral Therapies for Psoriasis: A Comprehensive Review (Q28071475) (← links)
- Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA (Q31034056) (← links)
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor (Q33659004) (← links)
- Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension (Q33729763) (← links)
- Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion (Q33903491) (← links)
- Etiology and management of pyoderma gangrenosum: a comprehensive review (Q34030811) (← links)
- Cytokine modulators in the treatment of sarcoidosis (Q34190083) (← links)
- Disposition, metabolism and mass balance of [14C]apremilast following oral administration (Q34209887) (← links)
- Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies (Q34253548) (← links)
- The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma (Q34491824) (← links)
- Apremilast. (Q34612877) (← links)
- Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity. (Q35825801) (← links)
- Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide (Q36025380) (← links)
- Current status and future prospects for biologic treatments of psoriasis (Q36057909) (← links)
- Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. (Q36061710) (← links)
- A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults (Q36734928) (← links)
- Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study (Q36866954) (← links)
- Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases (Q36923514) (← links)
- Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis (Q36942993) (← links)
- Current and potential immune therapies and vaccines in the management of psoriasis (Q36977772) (← links)
- Clinical potential of apremilast in the treatment of psoriatic arthritis (Q37031662) (← links)
- Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. (Q37046760) (← links)
- The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study (Q37104915) (← links)
- Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients (Q37136775) (← links)
- Biologics in dermatology (Q37277398) (← links)
- Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12. (Q37462071) (← links)
- Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis (Q37498810) (← links)
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease (Q37505449) (← links)
- The future of uveitis treatment (Q37554382) (← links)
- Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. (Q37557188) (← links)
- Advances in the treatment of moderate-to-severe plaque psoriasis (Q37868389) (← links)
- Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions (Q37870035) (← links)
- Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics (Q37893057) (← links)
- Therapy for sarcoidosis: evidence-based recommendations (Q37965606) (← links)
- Psoriasis drug discovery: methods for evaluation of potential drug candidates (Q37999088) (← links)
- Apremilast as a treatment for psoriasis (Q38019980) (← links)
- Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases (Q38032568) (← links)
- Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents (Q38098466) (← links)
- Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012). (Q38103909) (← links)
- Emerging therapies for rheumatoid arthritis (Q38110963) (← links)
- Burden of disease: psoriasis and psoriatic arthritis (Q38114850) (← links)
- Apremilast for the treatment of psoriatic arthritis (Q38202205) (← links)
- Investigational drugs for treating psoriatic arthritis (Q38206551) (← links)